Clinicopathological significance of altered metallothionein 2A expression in gastric cancer according to Lauren's classification

Chinese Medical Journal

Volumn 126, Issue 14, 2013, Pages 2681-2686

  Pan, Yuan Ming ^a   Xing, Rui ^b   Cui, Jian Tao ^b   Li, Wen Mei ^b   Lü, You Yong ^b  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b Department of Biochemistry and Molecular BiologyCancer Hospital of Peking University   (China)

Author keywords

Gastric cancer; Lauren's classification; Metallothionein 2A; Prognosis

Indexed keywords

MESSENGER RNA; METALLOTHIONEIN II;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER CLASSIFICATION; CANCER PROGNOSIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LAUREN CLASSIFICATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; STOMACH CANCER;

ADULT; AGED; CELL LINE, TUMOR; FEMALE; HUMANS; LOGISTIC MODELS; MALE; METALLOTHIONEIN; MICRORNAS; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; STOMACH NEOPLASMS;

EID: 84880475579     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20130579     Document Type: Article

References (30)

1. Wong H, Yau T. Molecular targeted therapies in advanced gastric cancer: does tumor histology matter? Therap Adv Gastroenterol 2013; 6: 15-31.
2. Shah MA, Khanin R, Tang L, Janjigian YY, Klimstra DS, Gerdes H, et al. Molecular classification of gastric cancer: a new paradigm. Clin Cancer Res 2011; 17: 2693-2701.
3. Wang BB, Liu CG, Lu P, Latengbaolide A, Lu Y. Log-normal censored regression model detecting prognostic factors in gastric cancer: a study of 3018 cases. World J Gastroenterol 2011; 17: 2867-2872.
4. Wong H, Yau T. Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine? Oncologist 2012; 17: 346-358.
5. Pedersen MO, Larsen A, Stoltenberg M, Penkowa M. The role of metallothionein in oncogenesis and cancer prognosis. Prog Histochem Cytochem 2009; 44: 29-64.
6. Jin R, Chow VT, Tan PH, Dheen ST, Duan W, Bay BH. Metallothionein 2A expression is associated with cell proliferation in breast cancer. Carcinogenesis 2002; 23: 81-86.
7. Cui Y, Wang J, Zhang X, Lang R, Bi M, Guo L, et al. ECRG2, a novel candidate of tumor suppressor gene in the esophageal carcinoma, interacts directly with metallothionein 2A and links to apoptosis. Biochem Biophys Res Commun 2003; 302: 904-915.
8. Tai SK, Tan OJ, Chow VT, Jin R, Jones JL, Tan PH, et al. Differential expression of metallothionein 1 and 2 isoforms in breast cancer lines with different invasive potential: identification of a novel nonsilent metallothionein-1H mutant variant. Am J Pathol 2003; 163: 2009-2019.
9. Somji S, Sens MA, Lamm DL, Garrett SH, Sens DA. Metallothionein isoform 1 and 2 gene expression in the human bladder: evidence for upregulation of MT-1X mRNA in bladder cancer. Cancer Detect Prev 2001; 25: 62-75.
10. Xie Y, Zhao YP, Chen G, Yuan CH, Li LJ. Metallothionein and its isoform genes expression in the human pancreatic cancer cell strains and their function. Acta Academiae Medicinae Sinicae (Chin) 2005; 27: 619-623.
11. Mitani T, Shirasaka D, Aoyama N, Miki I, Morita Y, Ikehara N, et al. Role of metallothionein in Helicobacter pylori-positive gastric mucosa with or without early gastric cancer and the effect on its expression after eradication therapy. J Gastroenterol Hepatol 2008; 23: e334-e339.
12. Chun JH, Kim HK, Kim E, Kim IH, Kim JH, Chang HJ, et al. Increased expression of metallothionein is associated with irinotecan resistance in gastric cancer. Cancer Res 2004; 64: 4703-4706.
13. Lim D, Jocelyn KM, Yip GW, Bay BH. Silencing the Metallo thionein-2A gene inhibits cell cycle progression from G1-to S-phase involving ATM and cdc25A signaling in breast cancer cells. Cancer Lett 2009; 276: 109-117.
14. Theocharis SE, Margeli AP, Koutselinis A. Metallothionein: a multifunctional protein from toxicity to cancer. Int J Biol Markers 2003; 18: 162-169.
15. Kim HG, Kim JY, Han EH, Hwang YP, Choi JH, Park BH, et al. Metallothionein-2A overexpression increases the expression of matrix metalloproteinase-9 and invasion of breast cancer cells. FEBS Lett 2011; 585: 421-428.
16. Datta J, Majumder S, Kutay H, Motiwala T, Frankel W, Costa R, et al. Metallothionein expression is suppressed in primary human hepatocellular carcinomas and is mediated through inactivation of CCAAT/enhancer binding protein alpha by phosphatidylinositol 3-kinase signaling cascade. Cancer Res 2007; 67: 2736-2746.
17. Tao X, Zheng JM, Xu AM, Chen XF, Zhang SH. Downregulated expression of metallothionein and its clinicopathological significance in hepatocellular carcinoma. Hepatol Res 2007; 37: 820-827.
18. Duncan EL, Reddel RR. Downregulation of metallothionein-IIA expression occurs at immortalization. Oncogene 1999; 18: 897-903.
19. Soo ET, Ng CT, Yip GW, Koo CY, Nga ME, Tan PH, et al. Differential expression of metallothionein in gastrointestinal stromal tumors and gastric carcinomas. Anat Rec (Hoboken) 2011; 294: 267-272.
20. Ebert MP, Gunther T, Hoffmann J, Yu J, Miehlke S, Schulz HU, et al. Expression of metallothionein II in intestinal metaplasia, dysplasia, and gastric cancer. Cancer Res 2000; 60: 1995-2001.
21. Wang Z, Wei W, Sarkar FH. miR-23a, a critical regulator of "migR"ation and metastasis in colorectal cancer. Cancer Discov 2012; 2: 489-491.
22. Jahid S, Sun J, Edwards RA, Dizon D, Panarelli NC, Milsom JW, et al. miR-23a promotes the transition from indolent to invasive colorectal cancer. Cancer Discov 2012; 2: 540-553.
23. Zhu LH, Liu T, Tang H, Tian RQ, Su C, Liu M, et al. MicroRNA-23a promotes the growth of gastric adenocarcinoma cell line MGC803 and downregulates interleukin-6 receptor. FEBS J 2010; 277: 3726-3734.
24. Wang B, Hsu SH, Frankel W, Ghoshal K, Jacob ST. Stat3-mediated activation of microRNA-23a suppresses gluconeogenesis in hepatocellular carcinoma by down-regulating glucose-6-phosphatase and peroxisome proliferator-activated receptor gamma, coactivator 1 alpha. Hepatology 2012; 56: 186-197.
25. An J, Pan Y, Yan Z, Li W, Cui J, Jiao Y, et al. MiR-23a in Amplified 19p13.13 Loci Targets Metallothionein 2A and Promotes Growth in Gastric Cancer Cells. J Cell Biochem 2013; Epub ahead of print.
26. Tan IB, Ivanova T, Lim KH, Ong CW, Deng N, Lee J, et al. Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology 2011; 141: 476-485.
27. Hyung WJ, Noh SH, Yoo CH, Huh JH, Shin DW, Lah KH, et al. Prognostic significance of metastatic lymph node ratio in T3 gastric cancer. World J Surg 2002; 26: 323-329.
28. Yamashita K, Sakuramoto S, Kikuchi S, Katada N, Kobayashi N, Watanabe M. Validation of staging systems for gastric cancer. Gastric Cancer 2008; 11: 111-118.
29. Sun Z, Xu YY, Wang ZN, Zhu Z, Zhang H, Huang BJ, et al. Macroscopic serosal classification predicts peritoneal recurrence for patients with gastric cancer underwent potentially curative surgery. Ann Surg Oncol 2011; 18: 1068-1080.
30. Solcia E, Klersy C, Vanoli A, Grillo F, Manca R, Tava F, et al. The contribution of cell phenotype to the behavior of gastric cancer. Gastric Cancer 2013; Epub ahead of print.